Sintx Technologies (LSE:0A8S) - Hisse Senedi Fiyatı, Haberler ve Analizler

0A8S Stoklara Genel Bakış

0A8S temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	1/6
Geçmiş Performans	0/6
Finansal Sağlık	5/6
Temettüler	0/6

Ödüller

Gelirin yılda 7.6% oranında artması öngörülüyor

Kazançlar son 5 yılda yılda 2.9% oranında arttı

Risk Analizi

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Anlamlı bir piyasa değeri yok ( $2M )

Önümüzdeki 3 yıl boyunca kazançların yılda ortalama 30% oranında düşmesi öngörülüyor

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

+ 2 daha fazla risk

Sintx Technologies, Inc. Rakipler

Deltex Medical Group

AIM:DEMG

UK£2.0m

Surgical Innovations Group

AIM:SUN

UK£5.1m

Belluscura

AIM:BELL

UK£19.4m

EMV Capital

AIM:EMVC

UK£12.8m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Sintx Technologies
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$3.18
52 Haftanın En Yüksek Seviyesi	US$116.40
52 Haftanın En Düşük Seviyesi	US$2.82
Beta	1.4
11 Aylık Değişim	-6.47%
3 Aylık Değişim	-36.40%
1 Yıllık Değişim	-97.26%
33 Yıllık Değişim	-99.99%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-99.99%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	0A8S	GB Medical Equipment	GB Pazar
7D	2.6%	3.3%	1.1%
1Y	-97.3%	16.3%	11.5%

Getiri vs. Endüstri: 0A8S geçen yıl % 11.2 oranında getiri sağlayan UK Medical Equipment sektörünün gerisinde kaldı.

Getiri vs Piyasa: 0A8S geçen yıl % 9.7 oranında getiri sağlayan UK Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is 0A8S's price volatile compared to industry and market?
0A8S volatility
0A8S Average Weekly Movement	24.5%
Medical Equipment Industry Average Movement	5.4%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	9.3%
10% least volatile stocks in GB Market	2.6%

İstikrarlı Hisse Senedi Fiyatı: 0A8S hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: 0A8S 'nin haftalık oynaklığı son bir yılda 44% dan 24% a düştü, ancak hâlâ UK hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1996	43	Eric Olson	www.sintx.com

Bir ileri seramik şirketi olan Sintx Technologies, Inc. Amerika Birleşik Devletleri'nde biyomedikal, teknik ve antipatojenik uygulamalar için silikon nitrür ile üretilen tıbbi cihazların araştırılması, geliştirilmesi ve ticarileştirilmesi ile ilgilenmektedir. Katı ve gözenekli silikon nitrür; silikon nitrit tozu; ve silikon nitrür kaplama ürünlerinin yanı sıra silikon nitrür kompozit malzemeler, polietereterketon ve polietereterketon sağlar. Şirket daha önce Amedica Corporation olarak biliniyordu.

Sintx Technologies, Inc. Temel Bilgiler Özeti

Sintx Technologies'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
0A8S temel i̇stati̇sti̇kler
Piyasa değeri	US$2.43m
Kazançlar(TTM)	-US$8.60m
Gelir(TTM)	US$3.13m

0.8x

P/S Oranı

-0.3x

F/K Oranı

0A8S aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
0A8S gelir tablosu (TTM)
Gelir	US$3.13m
Gelir Maliyeti	US$1.01m
Brüt Kâr	US$2.12m
Diğer Giderler	US$10.72m
Kazançlar	-US$8.60m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-11.51
Brüt Marj	67.72%
Net Kâr Marjı	-275.14%
Borç/Özkaynak Oranı	2.7%

0A8S uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

0A8S Stoklara Genel Bakış

Ödüller

Risk Analizi

Sintx Technologies, Inc. Rakipler

AIM:DEMG

UK£2.0m

AIM:SUN

UK£5.1m

AIM:BELL

UK£19.4m

AIM:EMVC

UK£12.8m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Sintx Technologies, Inc. Announces Key Executive Promotions: Ryan Bock, Phd, Named Chief Technology Officer and Ann Kutsch Promoted to President of Sintx Ta&T

Sintx Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $3.114779 million.

Second quarter 2024 earnings released: US$3.49 loss per share (vs US$122 loss in 2Q 2023)

Sintx Technologies, Inc. Announces Appointment of Eric K. Olson as Chief Executive Officer

Sintx Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $3.115475 million.

Sintx Technologies Regains Compliance with Nasdaq Bid Price Requirement

Recent updates

Sintx Technologies, Inc. Announces Key Executive Promotions: Ryan Bock, Phd, Named Chief Technology Officer and Ann Kutsch Promoted to President of Sintx Ta&T

Sintx Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $3.114779 million.

Second quarter 2024 earnings released: US$3.49 loss per share (vs US$122 loss in 2Q 2023)

Sintx Technologies, Inc. Announces Appointment of Eric K. Olson as Chief Executive Officer

Sintx Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $3.115475 million.

Sintx Technologies Regains Compliance with Nasdaq Bid Price Requirement

Sintx Technologies Declares 1-for-200 Reverse Stock Split Effective May 28, 2024 to Bring it into Compliance with the Minimum Bid Price Requirements for Maintaining the Listing on the Nasdaq Capital Market

New major risk - Financial position

First quarter 2024 earnings released: US$0.051 loss per share (vs US$0.13 loss in 1Q 2023)

Sintx Technologies Receives New Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

Sintx Technologies, Inc. has filed a Follow-on Equity Offering.

Full year 2023 earnings released: US$2.22 loss per share (vs US$54.67 loss in FY 2022)

Sintx Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $1.030519 million.

Sintx Technologies, Inc. Provides Estimated Revenue for the Fourth Quarter and Full Year Ended December 31, 2023

Third quarter 2023 earnings released: US$0.76 loss per share (vs US$11.02 loss in 3Q 2022)

Sintx Technologies, Inc., Annual General Meeting, Dec 05, 2023

SINTX Technologies Receives a Notice from Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

Sintx Technologies, Inc. Receives Phase II NIH Grant for Silicon Nitride-PEEK 3D Printed Composite Spinal Implants

New major risk - Revenue and earnings growth

No longer forecast to breakeven

Second quarter 2023 earnings released: US$0.61 loss per share (vs US$10.16 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.13 loss per share (vs US$11.51 loss in 1Q 2022)

Full year 2022 earnings released: US$54.67 loss per share (vs US$35.54 loss in FY 2021)

Sintx Technologies, Inc. has completed a Composite Units Offering in the amount of $12.04 million.

Sintx Technologies, Inc. has completed a Composite Units Offering in the amount of $12.04 million.

Insufficient new directors

Sintx Technologies, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Sintx Technologies Receives Notice from the Listing Qualifications Staff of Nasdaq

Third quarter 2022 earnings released: US$0.11 loss per share (vs US$0.095 loss in 3Q 2021)

Insufficient new directors

Sintx Technologies, Inc., Annual General Meeting, Dec 15, 2022

Sintx Technologies, Inc. has completed a Composite Units Offering in the amount of $4.7 million.

Sintx Technologies, Inc. Announces New Antibacterial Biomedical Patents and Expansion of Intellectual Property Portfolio

National Institutes of Health Announces Grant to Sintx Technologies for Development of 3D Printed Antimicrobial Trauma Device

Insufficient new directors

Insufficient new directors

Oxford Performance Materials and SINTX Technologies Collaboration Yields Major Breakthrough in Orthopedic & Dental Coatings

No longer forecast to breakeven

Second quarter 2022 earnings released: US$0.10 loss per share (vs US$0.089 loss in 2Q 2021)

Insufficient new directors

Sintx Technologies, Inc. (NasdaqCM:SINT) acquired Technology Assessment And Transfer, Inc. for 0.76 million.

Insufficient new directors

Insufficient new directors

No longer forecast to breakeven

Insufficient new directors

Full year 2021 earnings released: US$0.35 loss per share (vs US$1.01 loss in FY 2020)

No longer forecast to breakeven

Insufficient new directors

SINTX Technologies, Inc. Announces New Results on the Development of Manufacturing Technologies to Produce Fabrics Impregnated with SINTX Silicon Nitride, and the Antipathogenic Testing of These Fabrics

SINTX Technologies Receives A Notice from Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

No longer forecast to breakeven

Third quarter 2021 earnings released: US$0.095 loss per share (vs US$0.11 loss in 3Q 2020)

Sintx Technologies, Inc. Announces the Sale of First Silicon Nitride Antipathogenic Powder to O2TODAY

First quarter 2021 earnings released: US$0.11 loss per share (vs US$1.35 loss in 1Q 2020)

SINTX Technologies Announces New Product Brand, FleX SN, For Antipathogenic and Biomedical Applications

SINTX Technologies Files Multiple New U.S. and International Patent Applications

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında